Literature DB >> 19139304

Protean phenotypic features of the A3243G mitochondrial DNA mutation.

Petra Kaufmann1, Kristin Engelstad, Ying Wei, Romana Kulikova, Maryam Oskoui, Vanessa Battista, Dorcas Y Koenigsberger, Juan M Pascual, Mary Sano, Michio Hirano, Salvatore DiMauro, Dikoma C Shungu, Xiangling Mao, Darryl C De Vivo.   

Abstract

OBJECTIVE: To describe the spectrum of clinical symptoms, signs, and laboratory features associated with A3243G, a mitochondrial DNA point mutation that affects multiple organs with varying severity, making the diagnosis and treatment of these patients complex.
DESIGN: Cohort study.
SETTING: Columbia University Medical Center. PARTICIPANTS: A cohort of 123 matrilineal relatives from 45 families, including 45 fully symptomatic patients with mitochondrial myopathy, encephalomyopathy, lactic acidosis, and stroke-like episodes (syndrome), 78 carrier relatives, and 30 controls. MAIN OUTCOME MEASURES: Data gathered from standardized medical history questionnaires, neurological and ophthalmological examination forms, and laboratory tests. We compared data between 3 groups.
RESULTS: Mutation carriers' clinical and laboratory results frequently had many abnormalities. In addition to neurological symptoms, they often had cardiac, endocrine, gastrointestinal, and psychiatric symptoms.
CONCLUSIONS: The A3243G mutation carriers have multiple medical problems, suggesting that the A3243G mutation should be considered as an etiological factor in patients with multisystem clinical presentations or a family history compatible with matrilineal inheritance. Because some medical problems affecting A3243G mutation carriers are treatable, early detection and proactive management may mitigate the burden of morbidity.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19139304     DOI: 10.1001/archneurol.2008.526

Source DB:  PubMed          Journal:  Arch Neurol        ISSN: 0003-9942


  30 in total

1.  Metabolic profiles of exercise in patients with McArdle disease or mitochondrial myopathy.

Authors:  Nigel F Delaney; Rohit Sharma; Laura Tadvalkar; Clary B Clish; Ronald G Haller; Vamsi K Mootha
Journal:  Proc Natl Acad Sci U S A       Date:  2017-07-17       Impact factor: 11.205

2.  One mutation, three phenotypes: novel metabolic insights on MELAS, MIDD and myopathy caused by the m.3243A > G mutation.

Authors:  Karien Esterhuizen; J Zander Lindeque; Shayne Mason; Francois H van der Westhuizen; Richard J Rodenburg; Paul de Laat; Jan A M Smeitink; Mirian C H Janssen; Roan Louw
Journal:  Metabolomics       Date:  2021-01-12       Impact factor: 4.290

3.  Metabolic myopathies.

Authors:  Salvatore DiMauro; Caterina Garone; Ali Naini
Journal:  Curr Rheumatol Rep       Date:  2010-10       Impact factor: 4.592

4.  Mitochondrial myopathy associated with a novel 5522G>A mutation in the mitochondrial tRNA(Trp) gene.

Authors:  Ivo Barić; Ksenija Fumić; Danijela Petković Ramadža; Wolfgang Sperl; Franz A Zimmermann; Diana Muačević-Katanec; Zoran Mitrović; Leo Pažanin; Ljerka Cvitanović Šojat; Tihomir Kekez; Zeljko Reiner; Johannes A Mayr
Journal:  Eur J Hum Genet       Date:  2012-12-12       Impact factor: 4.246

5.  Mitochondrial dysfunction and cerebral metabolic abnormalities in patients with mitochondrial encephalomyopathy subtypes: Evidence from proton MR spectroscopy and muscle biopsy.

Authors:  Feng-Nan Niu; Hai-Lan Meng; Lei-Lei Chang; Hong-Yan Wu; Wei-Ping Li; Ren-Yuan Liu; Hui-Ting Wang; Bing Zhang; Yun Xu
Journal:  CNS Neurosci Ther       Date:  2017-07-11       Impact factor: 5.243

Review 6.  Risks associated with the stroke predisposition at young age: facts and hypotheses in light of individualized predictive and preventive approach.

Authors:  Jiri Polivka; Jiri Polivka; Martin Pesta; Vladimir Rohan; Libuse Celedova; Smit Mahajani; Ondrej Topolcan; Olga Golubnitschaja
Journal:  EPMA J       Date:  2019-02-20       Impact factor: 6.543

7.  Decreased hippocampal expression of calbindin D28K and cognitive impairment in MELAS.

Authors:  Valentina Emmanuele; Angels Garcia-Cazorla; Hua-Bin Huang; Jorida Coku; Beatriz Dorado; Etty P Cortes; Kristin Engelstad; Darryl C De Vivo; Salvatore Dimauro; Eduardo Bonilla; Kurenai Tanji
Journal:  J Neurol Sci       Date:  2012-04-05       Impact factor: 3.181

8.  Attitudes toward prevention of mtDNA-related diseases through oocyte mitochondrial replacement therapy.

Authors:  Kristin Engelstad; Miriam Sklerov; Joshua Kriger; Alexandra Sanford; Johnston Grier; Daniel Ash; Dieter Egli; Salvatore DiMauro; John L P Thompson; Mark V Sauer; Michio Hirano
Journal:  Hum Reprod       Date:  2016-03-02       Impact factor: 6.918

9.  Cerebral metabolic abnormalities in A3243G mitochondrial DNA mutation carriers.

Authors:  Nora Weiduschat; Petra Kaufmann; Xiangling Mao; Kristin Marie Engelstad; Veronica Hinton; Salvatore DiMauro; Darryl De Vivo; Dikoma Shungu
Journal:  Neurology       Date:  2014-01-29       Impact factor: 9.910

10.  ANALYSIS ON CENSORED QUANTILE RESIDUAL LIFE MODEL VIA SPLINE SMOOTHING.

Authors:  Yanyuan Ma; Ying Wei
Journal:  Stat Sin       Date:  2012-01-01       Impact factor: 1.261

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.